Hims & Hers Health, FDA and Trump
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...
Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...
The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...
Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $25.33 which represents a slight increase of $1.18 or 4.89% from the prior close of $24.15. The stock opened at ...
Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...
Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...
After going short the stock in June based on Hunterbrook Media’s reporting, Hunterbrook Capital said today it is long Hims & Hers Health.
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of ...
Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback